Modality– tag –
-
First PROTAC Therapy for Breast Cancer Approved, Opening New Avenues for Precision Medicine in Advanced, Metastatic Disease with Specific Mutations
Nature Medicine Journal (Facebook) International Overview A PROTAC therapy for breast cancer has received medical approval, pioneering a new era of precision medicine for patients with advanced or metastatic breast cancer harboring speci... -
Korro Bio Accelerates RNA Editing Platform into Clinic with First-in-Human Trial for Hyperammonemia and Designation of AATD Candidate
GlobeNewswire (via Korro Bio, Inc.) USA Overview Korro Bio has announced plans to initiate first-in-human clinical trials for its hyperammonemia treatment candidate, KRRO-121, in late 2026. Concurrently, the company designated KRRO-111 a... -
ProQR Therapeutics Marks Landmark: Axiomer RNA Editing Platform Achieves First Clinical Validation for Cholestatic Liver Disease Therapy
Quartr Sweden Overview ProQR Therapeutics has reported the first clinical validation of its proprietary Axiomer RNA editing platform, achieved through Phase 1 target engagement data for AX-0810. This candidate demonstrated modulation of ... -
Molecular Glue Development Accelerates: Gluetacs and Degron Advance Key Programs in Targeted Protein Degradation
GlobeNewswire Global Overview The field of molecular glues, a powerful targeted protein degradation (TPD) modality, is rapidly expanding with two significant clinical advancements: Gluetacs Therapeutics has initiated a Phase II trial for... -
First PROTAC Approval Validates Targeted Protein Degradation as a Breakthrough Modality for Cancer Treatment
Converge Bio Unknown Overview The FDA approval of vepdegestrant, developed by Arvinas and Pfizer, signifies a major milestone for targeted protein degradation (TPD). This first-in-class PROTAC, approved for ER+/HER2-, ESR1-mutated advanc... -
FDA Approves First PROTAC Vepdegestrant (ARV-471) for ER+/HER2- Breast Cancer, Ushering in a New Era of Targeted Protein Degradation
Journal of Medicinal Chemistry - ACS Publications USA Overview On May 1, 2026, the FDA approved vepdegestrant (ARV-471; Veppanu), making it the first heterobifunctional PROTAC protein degrader approved for clinical practice. Indicated fo... -
Samsung Biologics Acquires PolyPeptide in All-Cash Offer: Accelerating Multi-Modality Strategy and Global Network Expansion
PR Newswire South Korea Overview Samsung Biologics announced an all-cash offer to acquire PolyPeptide, accelerating its multi-modality strategy and expanding its global manufacturing network across the U.S., Europe, and India. This acqui... -
Nurix Therapeutics and Roche Secure HSR Clearance for Global Co-Development and Co-Commercialization Agreement of BTK Degrader Bexobrutideg
Nurix Therapeutics USA Overview Nurix Therapeutics announced HSR clearance for its global co-development and co-commercialization agreement with Roche for the BTK degrader bexobrutideg. Bexobrutideg is advancing in malignant hematology, ... -
Exponential Progression in Targeted Protein Degradation (TPD) Drug Discovery: New Modality Accelerates Drug Development
MarinBio USA Overview MarinBio published an article highlighting the exponential progression in Targeted Protein Degradation (TPD) drug discovery, establishing it as a primary, accelerating modality in novel drug development. TPD technol... -
Pfizer Discontinues Seagen-Developed Solid Tumor ADC Program SGN-MesoC2, Highlighting Persistent ADC Development Challenges
BioSpace USA Overview Pfizer has discontinued another Seagen-developed antibody-drug conjugate (ADC) program for solid tumors, SGN-MesoC2, just weeks after another Seagen-acquired ADC failed a Phase 3 lung cancer study. This cessation un...
12